🌍·15h agoIndustry
La FDA aprueba Foundayo™ (orforglipron) de Lilly, la única pastilla GLP-1 para la pérdida de peso que puede tomarse a cualquier hora del día sin restricciones de comida o agua
Publisher
E
Eli Lilly
US
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on investor.lilly.com
Leave the platform to read the original full article on the publisher site.
Source: Eli Lilly
Scope: Industry
Related coverage
More related coverage
Bristol Myers Squibb (Global)·7h ago
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
Eli Lilly·1d ago
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
Eli Lilly·2d ago
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Menicon·6h ago